Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRK-439 · 1 trial · 1 indication
• Incidence of AEs
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Participants will be treated with a single dose of SRK-439 or matching placebo. |
| Part B | EXPERIMENTAL | Participants will be treated with multiple doses of SRK-439 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo to SRK-439, subcutaneous administration |
| SRK-439 | DRUG | Single ascending dose, subcutaneous administration |
Key Inclusion Criteria: 1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent 2. BMI of ≥18 kg/m2 to ≤35 kg/m2 (inclusive) at screening Exclusion Criteria: 1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR ...
SRK-439 is an investigational small molecule being developed by Scholar Rock Holding Corporation (ticker: SRRK) for use in healthy adults. It is currently in Phase 1 clinical development, with a single trial studying its safety and tolerability in healthy volunteers.
SRK-439 targets myostatin, a protein that regulates muscle growth. By targeting myostatin, SRK-439 is designed to potentially modulate muscle-related pathways, though its exact therapeutic application is still under investigation in early-stage clinical trials.
SRK-439 is being developed by Scholar Rock Holding Corporation, a biopharmaceutical company traded on the stock exchange under the ticker symbol SRRK. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and pharmacokinetics in healthy adults.
SRK-439 is in Phase 1 clinical development. It is currently being studied in a single- and multiple-ascending dose trial in healthy adults, which is actively recruiting participants. The drug is investigational and has not yet been approved by regulatory authorities.
SRK-439 is being evaluated in a Phase 1 clinical trial with the identifier NCT07444294. This study is a single- and multiple-ascending dose trial in healthy adults, enrolling 76 participants in the United States. The trial is randomized, double-blind, and controlled, and is currently recruiting.